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In normal human kidney, NOS1 and soluble guanylate cyclase (sGC) are expressed in tubular epithelial cells, suggesting a physiological
autocrine NO signalling pathway. Therefore, we investigated both NOS1 and sGC expressions in benign and malignant renal
tumours. In addition, we examined the pattern of protein tyrosine nitration in normal and tumour tissue. NOS1 expression and
activity were found to be downregulated, correlating with the tumour grade, as shown by immunohistochemistry, quantitative RT–
PCR analysis, and histochemical detection of the NADPH-diaphorase activity of nitric oxide synthases (NOS). These results show
that the autocrine NO signalling pathway is maintained in benign tumours and lost in malignant tumours. In contrast, sGC expression
was maintained in renal tumours whatever the tumour type, a finding showing that tumour cells remain sensitive to the bioregulatory
role of exogeneous NO.. Finally, the staining pattern of protein tyrosine nitration, assessed by immunohistochemistry, parallelled that
of NOS1 expression in normal renal parenchyma and benign tumours, supporting the concept that protein nitration was accounted
for by NOS1 activity. In contrast, in malignant tumours, protein tyrosine nitration was accounted for by the production of reactive
nitrogen oxide species by the inflammatory infiltrate. Altogether, these findings argue for a pattern of NO signalling similar in normal
kidney and benign renal tumours, whereas it is completely different in malignant renal tumours.
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Nitric oxide synthases (NOS) are a family of enzymes that catalyse the
synthesis of NO, a gaseous free radical involved in both physiological
and pathological mechanisms depending on its concentration,
cellular source and microenvironment (Nathan, 1992; Kone, 1997;
Michel and Feron, 1997; Alderton et al, 2001). Three isoforms have
been described, two ‘constitutive’, Ca
2þ-dependent isoforms, that is,
NOS1 or neuronal NOS and NOS3 or endothelial NOS, and one
‘inducible’, Ca
2þ-independent isoform, NOS2 (for general reviews,
see Michel and Feron, 1997; Alderton et al, 2001).
We have recently shown that most tubular epithelial cells along
the human nephron strongly express NOS1, as well as soluble
guanylate cyclase (sGC), the intracellular target of NO., leading to
an autocrine NO signalling pathway in physiological conditions
(Jarry et al, 2003). Given that NO. has an important bioregulatory
role through its direct effects on sGC or by regulating the electron
transport chain in mitochondria (Wink et al, 1996; Wink and
Mitchell, 1998), one can wonder whether this autocrine signalling
pathway is maintained or not in renal tumours. NOS1 is of
particular interest since, besides synthesising NO., it can also
produce reactive oxygen species including superoxide ions (O2
 )
and hydrogen peroxide (H2O2) at low L-arginine concentrations
(Xia et al, 1996). In addition, the combination of equimolar
production of O2
  from several sources and NO. forms peroxyni-
trite (ONOO
 ), an oxidising and nitrating agent leading to the
nitration of protein tyrosine residues limited intracellularly within
close proximity of its source (Ischiropoulos et al, 1992; Beckman
et al, 1994; Jourd’heuil et al, 2001). Together, these findings
strongly suggest that protein tyrosine nitration is a post-
translational modification of proteins associated with NOS1
activity (Williams et al, 1998). This concept is in line with recent
findings suggesting that ONOO
  via protein tyrosine nitration
could have bioregulatory physiological roles, for example,
modulation of Naþ Kþ ATPase in rat kidney (Zhang et al,
2002). In pathological states, especially in inflammatory condi-
tions, protein tyrosine nitration can result from complex mechan-
isms involving the formation of NO2 . via the oxidation of
circulating nitrite NO2
  catalysed by peroxidase or haeme proteins,
a process able to target even cells devoid of the endogeneous NO
production machinery such as red blood cells (Ischiropoulos, 1998;
Wink and Mitchell, 1998, Grzelak et al, 2001).
Several lines of investigation have pointed to a bioregulatory
role associated with protein tyrosine nitration such as enzymatic
regulation, for example, inactivation of manganese superoxide
dismutase (MacMillan-Crow et al, 1996), cell proliferation and
apoptosis (Williams et al, 1998; Brito et al, 1999). It is thus
important to assess the extent of protein tyrosine nitration in
normal and tumour tissues.
In this context, we were prompted to examine in benign and
malignant renal tumours several issues, namely (i) the status of
NOS1 expression in renal tumours of various grades of malignancy
at the protein and mRNA levels; (ii) the persistence or not of an
autocrine NO signalling pathway in renal tumours assessed by the
Revised 6 January 2004; accepted 4 March 2004; published online 11 May
2004
*Correspondence: Dr A Jarry; E-mail: ajarry@sante.univ-nantes.fr
British Journal of Cancer (2004) 90, 2364–2369
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yimmunohistochemical detection of sGC; and (iii) the pattern of
protein tyrosine nitration in human normal kidney and in renal
tumours, assessed by immunohistochemical detection of 3-
nitrotyrosine. We used red blood cells in order to distinguish
protein tyrosine nitration resulting either from an intracellular
production of ONOO
  (negative staining of red blood cells) or
from the production by the inflammatory infiltrate of reactive
nitrogen species able to act at distance from their source (positive
staining of red blood cells).
MATERIALS AND METHODS
Tissue specimens
Tumour tissue and normal tissue at distance from the tumour were
collected from 32 patients undergoing nephrectomy for oncocy-
toma (six cases), chromophobe renal cell carcinoma (RCC) (four
cases) and clear cell RCC (22 cases: five cases Fu ¨hrman grade I;
seven cases Fu ¨hrman grade II; seven cases Fu ¨hrman grade III;
three cases Fu ¨hrman grade IV). For each case, samples of tumour
and normal tissue were snap frozen and stored in liquid nitrogen,
and also fixed in formalin and embedded in paraffin. These
samples were collected according to the guidelines of the French
Ethics Committee for Research on Human Tissues.
Immunohistochemistry
Immunohistochemistry was performed on 5mm formalin-fixed
paraffin sections of different renal tumours with the polyclonal N-
terminus NOS1, the sCG and the 3-nitrotyrosine antibodies, and
on 5mm acetone-fixed cryostat sections for staining with the
monoclonal C-terminus NOS1, the NOS2 and the NOS3 antibodies.
The specificity and conditions of use of primary antibodies
directed to NOS isoforms are listed in Table 1. First, endogenous
biotin was blocked using a sequential avidin–biotin treatment
(Biotin blocking system, Dako, Trappes, France). Then, immuno-
histochemistry was performed using a streptavidin–biotin method
(Histostain Plus kit, LAB-SA detection system, Zymed, Clini-
science, Montrouge, France), according to the manufacturer’s
instructions. Aminoethyl carbazol (AEC) or diaminobenzidine
(DAB) were used as chromogens. The sections were slightly
counterstained with haematoxylin and mounted. Negative controls
were performed by omitting the first antibody. To verify the
specificity for nitrotyrosine, the antinitrotyrosine antibody was
pretreated for at least 1h at room temperature with 3-nitrotyrosine
(Sigma, 10mM solution, pH 7.4) prior to incubation on tissue
sections. Immunohistochemical staining was assessed by two
independent observers (KR, AJ) including a pathologist (KR).
NADPH-diaphorase histochemistry
In total, 5mm cryostat sections were fixed for 15min in a freshly
made paraformaldehyde solution (4% wv
 1 in PBS) and then
washed four times in PBS. The NADPH-diaphorase (NADPH-d)
activity of NOS, which is paraformaldehyde-resistant, was demon-
strated by enzymatic reduction of nitroblue tetrazolium in the
presence of NADPH, as previously described (Weinberg et al,
1996). Briefly, slides were incubated in 1  PBS containing
1mgml
 1 NADPH (Roche Molecular Biochemicals, Meylan,
France) and 0.4mgml
 1 NBT (Roche Molecular Biochemicals)
for 30min at 371C, washed in PBS, dehydrated and mounted
without any counterstaining. NADPH was omitted in negative
controls.
Quantitative RT–PCR analysis of NOS1 expression
Total RNA was extracted from four cases of Fu ¨hrman III RCC and
normal renal parenchyma from the same patients using the
GenElute Mammalian Total RNA kit (Sigma, Saint-Quentin
Fallavier, France) and the Fast Prep cell disrupter (Bio 101, Q-
BIOgene, Illkirch, France). RNA (5mg) was denaturated at 721C for
3min and then reverse transcribed for 60min at 421Ci na2 0 ml
reaction volume (50mM Tris-HCl pH 8.3, 75mM KCl, 3mM MgCl2,
10mM DTT) containing 0.5mg of random hexamers (Promega,
Charbonnie `res, France), dNTPs (1mM each), RNasin (50U) and
RnaseH
  MMLV reverse transcriptase (200U).
The amplification conditions of the NOS1 and b-actin templates
were optimised for the Rotorgene 2000 instrument (Ozyme, Saint
Quentin en Yvelines, France). PCR amplifications were performed
using Titanium Taq DNA polymerase (Clontech, Ozyme). The
reaction mixture contained 2ml of the supplied 10  Titanium Taq
PCR buffer (containing magnesium chloride), 2ml of a 1/1000
dilution of SYBR Green I (Roche Molecular Biochemicals), 1mlo f
each primer (0.4mM each), 0.4ml of Titanium Taq DNA polymer-
ase, 0.5ml of dNTPs (10mM each) and PCR-grade water to a
volume of 15ml. Microtubes (0.2ml) were loaded with 15ml of this
master mix and 5ml of the template (cDNA diluted 1/50) and the
run was initiated. The cycling conditions were as follows:
Table 1 Antibodies used for immunohistochemistry
Protein
detected
Type of antibody
source
Antigen (amino acids)
C- or N-terminus
Immunohistochemistry: Frozen (F),
paraffin (P)/dilution
NOS1 Monoclonal Synthetic human peptide (F)/1:100
Transduction Lab C-terminus (1095–1289)
NOS1 Polyclonal Rat recombinant protein (P)/1:200
Zymed N-terminus (last 200 aa)
NOS2 Polyclonal Synthetic human peptide (F)/1:500
Santa Cruz C-terminus
NOS3 Polyclonal Synthetic human peptide (F)/1:300
Transduction Lab C-terminus
sGC Polyclonal
Cayman
Synthetic human peptide
from a1 and b1 subunits
(P)/1:300
3-NTY Polyclonal Nitrated KLH (P)/1:300
Upstate Biotechnology
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denaturation for 5s at 951C, annealing for 10s at 631C and
extension for 20s at 721C. To exclude primer-dimer artifacts,
fluorescence was not measured at the end of the extension step, but
a separate detection step was added (15s) at a temperature (881C)
above the melting point of primer-dimers and below the melting
point of the specific PCR product (921C).
Primers NOS1 sense (50-TCT CCT CCT ACT CTG ACT CC-30)
and NOS1 antisense (50-TTG TGG ACA TTG GAT AGA CC-30)
were designed from the sequence of the human NOS1 cDNA
(accession number NM-000620). They were selected for binding to
separate exons (exon 17 and exon 20, respectively) to avoid false
positive results arising from amplification of contaminating
genomic DNA.
After completion of the cycling process, samples were subjected
to a temperature ramp from 63 to 991C, with continuous
fluorescence monitoring for melting curve analysis. For each
amplification, apart from primer-dimers, a single narrow peak was
obtained at the expected melting temperature (921C), indicating
specific amplification without significant by-products.
An external standard curve was generated with serial five-fold
dilutions of cDNA (1:20, 1:100 and 1:500) prepared from normal
kidney RNA. The reference curve was constructed by plotting the
relative amounts of these dilutions vs the corresponding Ct
(threshold cycle) values. The correlation coefficient of these curves
was always greater than 0.99. The amount of NOS1 transcript was
calculated from these standard curves using the RotorGene
software. A relative unit of 100 was assigned for the standard
cDNA diluted 1/500. Samples were tested in triplicate and the
average values were used for quantification.
For each sample, the relative amount of human b-actin cDNA
was determined, as described for NOS1 with primers 50-CCT TCC
TGG GCA TGG AGT CCT G-30 (actin sense) and 50-GGA GCA ATG
ATC TTG ATC TTC-30 (actin antisense). The ratio between the
relative amount of NOS1 and b-actin was then calculated to
compensate for variations in quantity or quality of starting mRNA
as well as for differences in reverse transcriptase efficiency.
RESULTS
Downregulation of NOS1 expression in high-grade clear
cell RCC detected by immunohistochemistry, associated
with a loss of the NADPH-diaphorase activity of NOS
We assessed the expression of NOS1 in tumour samples by using
an antibody directed to the C-terminus part of NOS1 on cryostat
sections. To confirm the staining pattern, we used another
antibody directed to the N-terminus part of NOS1, on paraffin
sections of a few cases of each type of tumour. The overall staining
pattern was found identical with both antibodies (Table 2). NOS1
was expressed in tumour cells of oncocytomas, chromophobe RCC
and in few cells of Fu ¨rhman I and II clear cell RCC. Conversely,
Fu ¨rhman III and IV clear cell RCC never expressed NOS1
(Figure 1).
We then confirmed that the downregulation of NOS1 immuno-
reactivity was in parallel with a loss of the NOS reductase activity.
The results of the histochemical detection of NOS reductase
activity by NADPH-d histochemistry, performed on paraformal-
dehyde-fixed cryostat sections of the different renal tumours, are
summarised in Table 2. A high NADPH-d activity was detected in
tumour cells of benign tumours and tumours of low malignancy,
that is, oncocytoma and chromophobe RCC, respectively. A lower
and heterogeneous staining pattern was observed in tumour cells
of low-grade clear cell RCC (Fu ¨rhman grade I and rarely grade II).
No activity was detected in Fu ¨rhman grade III or IV clear cell RCC.
In all type of tumours, endothelial cells displayed a NADPH-d
activity.
The downregulation of NOS1 expression in high-grade
clear cell RCC is correlated with a dramatic decrease
in NOS1 mRNA levels
In order to determine whether the lack of NOS1 expression was
correlated with its mRNA level, the amount of NOS1 mRNA was
measured by real-time quantitative RT–PCR in four specimens of
grade III clear cell RCC and the corresponding normal tissue. As
shown in Figure 2, the level of NOS1 mRNAs relative to b-actin
levels was undetectable in the tumour tissue of grade III clear cell
RCC, whereas high NOS1 levels were found in the corresponding
normal renal tissue.
The downregulation of NOS1 expression in high-grade
clear cell RCC is not associated with an upregulation
of other NOS isoforms expression in tumour cells
To further confirm that the loss of NOS1 expression was not
associated with an upregulation of other NOS isoforms, we
assessed both NOS2 and NOS3 expression by immunohistochem-
istry in the renal tumours. In our study we did not find any NOS2
expression in tumour cells whatever the tumour type or grade.
Only a few NOS2-positive inflammatory cells were noted within the
stromal reaction and served as an internal positive control. NOS3
was never found in tumour cells, but, as expected from the
NADPH-d assay, endothelial cells were stained with the NOS3
antibody.
The downregulation of NOS1 expression in high-grade
clear cell RCC is not associated with a loss of sGC, the
physiological intracellular target of NO.
We assessed by immunohistochemistry the expression of sGC in
two cases of each tumour type. The sGC was expressed in tumour
cells of oncocytomas, chromophobe RCC and clear cell RCC
whatever the Fu ¨rhman grade (not shown).
Pattern of protein nitration in renal tumours compared
with normal renal parenchyma
As protein tyrosine nitration is a post-translational modification of
many proteins that can be accounted for by several mechanisms
that is, formation of ONOO
  or other reactive nitrogen species
(NO2 .,N O 2Cl) (Ischiropoulos, 1998; Wink and Mitchell, 1998), it
was important to design a protocol to distinguish between these
different processes. Interestingly, as the chemistry of ONOO
  is
Table 2 NADPH-diaphorase activity of NOS and NOS1 expression in
renal tumours
NOS1
immunohistochemistry
Tumour type
Cryostat
sections
(n¼29)
Paraffin
sections
(n¼9)
NADPH-d
activity (n¼29)
Oncocytoma 5/5 2/2 5/5
Chromophobe RCC 2/2 2/2 2/2
Clear cell RCC
Fu ¨rhman I 5/5 1/1 5/5
Fu ¨rhman II 1/7 1/2 1/7
Fu ¨rhman III 0/7 0/1 0/7
Fu ¨rhman IV 0/3 0/1 0/3
NADPH-diaphorase histochemistry was performed on cyrostat sections, and NOS1
immunohistochemistry on cryostat or paraffin sections depending on the antibody
used (see Material and Methods). The numbers indicated in the table represent the
number of positive tumours over the total number of tumours studied.
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ylimited within close proximity of its source, only proteins located
proximally to its site of generation can be nitrated. In contrast,
other nitrating species, including the oxidation of NO2
  into NO2 . in
the presence of myeloperoxidase or other haeme proteins (Grzelak
et al, 2001) as well as the formation of NO2Cl, are known to have a
long range of action and nitrate proteins at distance from their
production site, that is, inflammatory cells (Wink and Mitchell,
1998; Espey et al, 2002). Since red blood cells are devoid of NOS,
the assessment of red blood cells nitration can thus be considered
as a simple index of the production in the cellular environment of
reactive nitrogen species with a long range of action.
We assessed the pattern of protein nitration by immunohis-
tochemistry in three cases of normal parenchyma and in three
cases of each tumour type. In normal renal parenchyma the overall
staining pattern was identical to the NOS1 expression pattern
(Table 3 and Figure 3A), with no red blood cell nitration. In benign
tumours (i.e. oncocytoma), the staining pattern of nitration was
similar to the one of NOS1 with a strong, granular and
homogeneous staining of tumour cells, and without any staining
of red blood cells in the absence of inflammatory infiltrate (Table 4
and Figure 3B). In contrast, in malignant tumours (i.e. chromo-
phobe RCC and clear cell RCC), surrounded by an important
inflammatory infiltrate, the pattern of protein nitration was highly
heterogeneous, with some parts of the tumour strongly stained and
others devoid of any staining. In addition, there was an intense
staining of red blood cells in vessels within or near the tumour
(Table 4 and Figure 3C).
0
1.8
1.6
1.4
1.2
0
0.8
0.6
0.4
0.2
N
O
S
1
/
a
c
t
i
n
N1 N2                                   N3 N4 T2 T3 T1 T4
Figure 2 Quantitative analysis of NOS1 mRNA in grade III clear cell
RCC. Total RNAs were extracted from the tumour of four patients
undergoing surgery for grade III clear cell RCC (T1–T4) and also from the
corresponding normal renal parenchyma (N1–N4) taken at distance from
the tumour, reversed transcribed and submitted to real time PCR as
described in Material and Methods. Amounts of NOS1 amplification
products were normalised to b-actin. In the four cases, NOS1 mRNAs
were beyond the limit of detection in the tumours whereas they were
always present in the corresponding normal renal parenchyma.
Table 3 Immunostaining pattern of protein nitration compared with that
of NOS1 in the normal human renal parenchyma
Immunostaining pattern
Intrarenal distribution 3-nitrotyrosine NOS1
a
Glomerulus
Mesangial cells   
Parietal cells 7  
Podocytes 77
Proximal tubules + +
Distal tubules + +
Henle’s loops + +
Collecting ducts + +
Red blood cells   
3-Nitrotyrosine immunohistochemistry was performed on paraffin section of three
cases of normal renal parenchyma.  ¼no staining; 7¼heterogeneous positive
staining; +¼homogeneous positive staining.
aNOS1 staining pattern already fully
described in normal kidney in a previous paper (Jarry et al, 2003).
Figure 1 Correlation of NOS1 expression in human renal tumours with
the tumour grade. Immunolocalisation of NOS1 on paraffin sections of a
representative case of benign tumour (oncocytoma: A), low-malignant
carcinoma (chromophobe RCC: B) and grade III clear cell RCC (C).
Tumour cells were strongly labelled with the NOS1 antibody in the
oncocytoma and chromophobe cell carcinoma, whereas they were
negative in the high-grade RCC (original magnification  200).
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yDISCUSSION
Our results show a modulation of NOS1 expression correlating
with the pathological grading and the malignant potential of renal
tumours. These results support and extend previous findings
showing that Ca
2þ-dependent NOS activity, measured by
L-arginine to L-citrulline conversion assay, was significantly lower
in RCCs than in normal renal parenchyma and inversely correlated
with the tumour grade according to Fu ¨hrman’s classification
(Jansson et al, 1998). In this study the calcium-independent
inducible NOS activity was undetectable in RCC (Jansson et al,
1998). Similarly, in our study, NOS2 was never detected by
immunohistochemistry in all the tumours tested, thus suggesting
that the loss of NOS1 expression was not counterbalanced by
induction of NOS2 expression in tumour cells. The downregulation
of NOS1 expression in high-grade clear cell RCC is associated with
the absence of NOS1 mRNA, as shown by real-time RT–PCR.
Numerous splicing variants of the NOS1 gene have been described
(Forstermann et al, 1998). Most of them differ in their 50 end. One
cannot exclude that high-grade clear cell RCC tumour cells express
a specific splicing variant of NOS1 mRNA, which would not have
been detected in our experimental conditions. But this is unlikely,
since the PCR primers were designed to span a large central area of
the transcript. Furthermore, we used on purpose two antibodies
specific for the N- and C-terminus part of NOS1, which should
have allowed us to detect a truncated protein. Therefore, we can
conclude that the absence of detectable NOS1 mRNA is probably
due to a significant decrease in NOS1 gene transcription or/and in
NOS1 mRNA stability, although a deletion or a mutation in the
NOS1 gene cannot yet be excluded. Further investigations are
needed to elucidate this issue.
Another interesting finding of our study is that the loss of NOS1
expression in high-grade RCC is not associated with a loss of sGC
expression. This result leads to two conclusions: (i) the autocrine
signalling pathway of NO previously observed in normal human
tubular epithelial cells (Jarry et al, 2003) is maintained in benign
tumours and low malignant potential RCC but not in high-grade
clear cell RCC, and (ii) the persistence of sGC expression in all
tumour types implies that tumour cells remain sensitive to the
bioregulatory roles of exogeneous NO.
The third major finding of this study concerns the pattern of
protein tyrosine nitration, which is identical in normal kidney and
in benign renal tumours, but completely different in malignant
tumours. Nitration is a covalent modification of the tyrosine
residues of some proteins with activating or inhibitory activities
that could be involved in physiological conditions as well as in
pathological states such as inflammatory processes and tumours
Figure 3 Changes in the immunostaining pattern of protein tyrosine
nitration between normal human kidney/benign tumour and RCC.
Immunodetection of 3-nitrotyrosine on paraffin sections. (A) In normal
renal parenchyma, most of the tubular epithelial cells along the nephron
were labelled, with a variable staining intensity. In glomeruli, some of the
podocytes and parietal cells scored positive. Red blood cells were not
labelled. (B) In oncocytoma, a strong, granular and homogeneous staining
of tumour cells was noted. Red blood cells were not labelled, and there
was no inflammatory infiltrate. (C) In contrast, in malignant tumours (a case
of grade III clear cell RCC is shown), the pattern of protein tyrosine
nitration was heterogeneous. Red blood cells (*) were strongly stained and
an inflammatory infiltrate was present (original magnification  200).
Table 4 Pattern of protein nitration in renal tumours: correlation with
the nitration of red blood cells and the degree of the inflammatory infiltrate
3-Nitrotyrosine
immunohistochemistry
Tumour type Tumour cells Red blood cells
Inflammatory
infiltrate
Oncocytoma Homogeneous   
Chromophobe RCC Heterogeneous + +
Clear cell RCC
Fu ¨rhman I Heterogeneous + ++
Fu ¨rhman II Heterogeneous + +++
Fu ¨rhman III Heterogeneous + +++
Fu ¨rhman IV Heterogeneous + +++
3-Nitrotyrosine immunohistochemistry was performed on paraffin sections of three
cases of each tumour type. The immunostaining of tumour cells was referred to as
‘homogeneous’ when a majority of cells was stained with the same intensity and as
‘heterogeneous’ when some parts of the tumour were stained and others devoid of
any staining. Immunostaining of red blood cells: ( ) denotes absent and (+) denotes
majority of red blood cells stained. Semiquantitative evaluation of the inflammatory
infiltrate: ( ) means absence of infiltrate; (+) denotes a mild infiltrate, (++) a
moderate infiltrate and (+++) an abundant infiltrate.
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2002; Ischiropoulos, 2003; Schopfer et al, 2003). Nitration process
can result from several mechanisms, that is, intracellular action of
ONOO
  and long-range action of other reactive nitrogen species
produced by inflammatory cells. The most well-known mechanism
of protein nitration is the ONOO
  pathway, resulting from the
reaction of equimolar NO. and O2
 , a phenomenon restricted to an
organelle or cellular compartment such as mitochondria (Radi
et al, 2002; Ghafourifar and Colton, 2003). Our observation of a
granular staining pattern with the antinitrotyrosine antibody,
identical to that of NOS1, in tubular epithelial cells of normal renal
parenchyma and in oncocytoma, is in line with this concept of
ONOO
  chemistry limited to close proximity of its source. In
addition, we can rule out the involvement of long-range acting
nitrogen species since red blood cells are devoid of any staining in
normal renal tissue and in oncocytoma. In malignant tumours
containing an important inflammatory infiltrate, the interpretation
of protein nitration pattern is more complex. Indeed, other
nitrating species known to have a long range of action are
produced by inflammatory cells and result from the oxidation of
circulating nitrite NO2
  into NO2 ., a reaction catalysed by
myeloperoxidase or other haeme proteins in the presence of
H2O2 (Wink and Mitchell, 1998). In addition, the Cl
  transfer from
HOCl to NO2
  generates NO2Cl, a nitrating agent (Bian et al, 2003).
Since we noticed a downregulation of NOS1 expression in most
malignant renal tumours, we can suggest that the reactive nitrogen
species released by the inflammatory infiltrate are responsible for
the heterogeneous nitrated staining pattern observed in these
malignant tumours. This interpretation was strongly supported by
the staining of red blood cells, a cell type devoid of any
endogeneous source of NO.
In conclusion, our study helped decipher the pattern of NO
signalling in renal tumours of different grades compared with that
of normal renal parenchyma. The bioregulatory activity of NO is
similar in benign tumours and in normal kidney, whereas there is a
shift of NO signalling in high-grade malignant tumours, with a loss
of endogeneous NO synthesis, but the maintenance of sGC, the
receptor for exogeneous NO. The demonstration of nitrated
proteins in renal tumours implies that exogeneous NO, especially
reactive nitrogen species produced by inflammatory cells, have an
impact on cancer cells, whose biological significance remain to be
determined.
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